Biogen shares fell Friday after the head of the FDA called for an investigation into the recent approval of the company’s Alzheimer’s drug, Aduhelm. Source


And get notified everytime we publish a new Important announcements. We will not email you often, unless there are important things that need to get in touch with you, such as added new tools or new domain names.